Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.55 |
| ▸ | CA2 | P00918 | 3/20 | 0.55 |
| ▸ | CA12 | O43570 | 2/20 | 0.55 |
| ▸ | CA9 | Q16790 | 2/20 | 0.55 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | CA7 | P43166 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 4/20 | 0.50 |
| ▸ | ACR | P10323 | 2/20 | 0.50 |
| ▸ | HGFAC | Q04756 | 1/20 | 0.50 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.50 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.50 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.50 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.50 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.50 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.50 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2775631 | 1.00 | CA1 (0.55) | CA1CA2CA12CA9CA14 | |
| SCHEMBL13617864 | 1.00 | CA1 (0.55) | CA1CA2CA12CA9CA14 | |
| Urea SCHEMBL20838278 | 0.83 | CA1 (0.70) | CA1CA2CA12CA9CA14 | |
| SCHEMBL30506553 | 0.82 | LOXL2 (0.54) | CA1CA2CA12CA9CA14 | |
| SCHEMBL2773914 | 0.82 | LOXL2 (0.54) | CA1CA2CA12CA9CA14 | |
| SCHEMBL66472 | 0.82 | LOXL2 (0.54) | CA1CA2CA12CA9CA14 | |
| SCHEMBL2773919 | 0.82 | LOXL2 (0.54) | CA1CA2CA12CA9CA14 | |
| SCHEMBL30008510 | 0.82 | LOXL2 (0.54) | CA1CA2CA12CA9CA14 | |
| SCHEMBL23600 | 0.80 | CA1 (0.80) | CA1CA2CA12CA9CA14 | |
| SCHEMBL28993944 | 0.80 | CA1 (0.80) | CA1CA2CA12CA9CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3233842-B1 | BICYCLOHETEROARYL-HETEROARYL-BENZOIC ACID COMPOUNDS AS RETINOIC ACID RECEPTOR BETA (RARB) AGONISTS | KING S COLLEGE LONDON (GB) | 2025-03-26 | — | — | EP | disclosed |
| EP-3704113-B1 | BRIDGED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-10-11 | — | — | EP | disclosed |
| WO-2023038500-A1 | COMPOUND FOR DEGRADING ENL PROTEIN AND MEDICAL USES THEREOF | 주식회사 유빅스테라퓨틱스 | 2023-03-16 | — | — | WO | disclosed |
| US-11584741-B2 | Crystalline forms of 4-(5-(4,7-dimethylbenzofuran-2-yl)-1,2,4-oxadiazol-3-yl)benzoic acid and processes for their preparation | KING'S COLLEGE LONDON (GB) | 2023-02-21 | — | — | US | disclosed |
| US-11584741-B2 | Crystalline forms of 4-(5-(4,7-dimethylbenzofuran-2-yl)-1,2,4-oxadiazol-3-yl)benzoic acid and processes for their preparation | KING'S COLLEGE LONDON (GB) | 2023-02-21 | — | — | US | disclosed |
| US-11401265-B2 | Bicycloheteroaryl-heteroaryl-benzoic acid compounds as retinoic acid receptor beta (RARβ) agonists | KING'S COLLEGE LONDON | 2022-08-02 | — | — | US | disclosed |
| US-20220204490-A1 | Substituted 4-[5-(Benzofuran-2-yl)-1,2,4-Oxadiazol-3-yl]Benzoic Acid Compounds for Use in Therapy for Neuropathic Pain | KING'S COLLEGE LONDON (GB) | 2022-06-30 | — | — | US | disclosed |
| US-20220204490-A1 | Substituted 4-[5-(Benzofuran-2-yl)-1,2,4-Oxadiazol-3-yl]Benzoic Acid Compounds for Use in Therapy for Neuropathic Pain | KING'S COLLEGE LONDON (GB) | 2022-06-30 | — | — | US | disclosed |
| EP-3976028-A1 | SUBSTITUTED 4-[5-(BENZOFURAN-2-YL)-1,2,4-OXADIAZOL-3-YL]BENZOIC ACID COMPOUNDS FOR USE IN THERAPY FOR NEUROPATHIC PAIN | King's College London (GB) | 2022-04-06 | — | — | EP | disclosed |
| US-20210230151-A1 | Crystalline Forms of 4-(5-(4,7-Dimethylbenzofuran-2-YL)-1,2,4-Oxadiazol-3-YL)Benzoic Acid and Processes for Their Preparation | KING'S COLLEGE LONDON (GB) | 2021-07-29 | — | — | US | disclosed |
| EP-3215505-A1 | PIPERIDINYLPYRAZOLOPYRIMIDINONES AND THEIR USE | Bayer Pharma Aktiengesellschaft (DE) | 2017-09-13 | — | — | EP | disclosed |
| EP-2193125-B1 | OXADIAZOLE DERIVATIVES | MERCK SERONO SA (CH) | 2017-01-11 | — | — | EP | disclosed |
| WO-2016097004-A1 | BICYCLOHETEROARYL-HETEROARYL-BENZOIC ACID COMPOUNDS AS RETINOIC ACID RECEPTOR BETA (RARβ) AGONISTS | KING'S COLLEGE LONDON (GB) | 2016-06-23 | — | — | WO | disclosed |
| WO-2016071216-A1 | PIPERIDINYLPYRAZOLOPYRIMIDINONES AND THEIR USE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-05-12 | — | — | WO | disclosed |
| US-8202865-B2 | Oxadiazole derivatives | MERCK SERONO SA (CH) | 2012-06-19 | — | — | US | disclosed |
| US-8202856-B2 | Triazole oxadiazoles derivatives | MERCK SERONO SA (CH) | 2012-06-19 | — | — | US | disclosed |
| US-20100305092-A1 | TRIAZOLE OXADIAZOLES DERIVATIVES | MERCK SERONO SA (CH) | 2010-12-02 | — | — | US | disclosed |
| US-20100240658-A1 | Oxadiazole Derivatives | MERCK SERONO SA (CH) | 2010-09-23 | — | — | US | disclosed |
| EP-2193125-A2 | OXADIAZOLE DERIVATIVES | Merck Serono S.A. (CH) | 2010-06-09 | — | — | EP | disclosed |
| WO-2009043889-A2 | OXADIAZOLE DERIVATIVES | MERCK SERONO S.A. (CH) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11401265-B2 | Bicycloheteroaryl-heteroaryl-benzoic acid compounds as retinoic acid receptor beta (RARβ) agonists | RARB, RARA, RXRB | CA1 3686/4885CA2 3851/4885CA12 4441/4885 |
| US-20100305092-A1 | TRIAZOLE OXADIAZOLES DERIVATIVES | OXA1L, RO60, PDCD11 | CA1 2310/4885CA2 3172/4885CA12 3383/4885 |
| US-11584741-B2 | Crystalline forms of 4-(5-(4,7-dimethylbenzofuran-2-yl)-1,2,4-oxadiazol-3-yl)benzoic acid and processes for their preparation | RARB, RXRB, RARA | CA1 1838/4885CA2 2392/4885CA12 3766/4885 |
| US-20100240658-A1 | Oxadiazole Derivatives | OXA1L, RO60, NQO2 | CA1 2829/4885CA2 2987/4885CA12 3369/4885 |
| US-20210230151-A1 | Crystalline Forms of 4-(5-(4,7-Dimethylbenzofuran-2-YL)-1,2,4-Oxadiazol-3-YL)Benzoic Acid and Processes for Their Preparation | RARB, RXRB, RARA | CA1 2715/4885CA2 2591/4885CA12 4241/4885 |
| US-20220204490-A1 | Substituted 4-[5-(Benzofuran-2-yl)-1,2,4-Oxadiazol-3-yl]Benzoic Acid Compounds for Use in Therapy for Neuropathic Pain | OPRK1, TRPV1, TRPA1 | CA1 2854/4885CA2 633/4885CA12 3544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.